PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
These metrics indicate whether the stock trades cheaply or expensively relative to its fundamentals. Value investors use them to find mispricings—buying stocks that appear undervalued, with solid long-term prospects and limited downside risk.
-3.10
Negative P/E while Healthcare median is -1.31. Seth Klarman would scrutinize path to profitability versus peers.
No Data
No Data available this quarter, please select a different quarter.
4.31
P/B exceeding 1.5x Healthcare median of 2.80. Jim Chanos would check for potential asset write-down risks.
-13.19
Negative FCF while Healthcare median P/FCF is -7.17. Seth Klarman would investigate cash flow improvement potential.
-13.22
Negative operating cash flow while Healthcare median P/OCF is -0.19. Seth Klarman would investigate operational improvement potential.
4.31
Fair value ratio exceeding 1.5x Healthcare median of 2.80. Jim Chanos would check for valuation bubble risks.
-8.05%
Negative earnings while Healthcare median yield is -0.31%. Seth Klarman would investigate path to profitability.
-7.58%
Negative FCF while Healthcare median yield is -0.28%. Seth Klarman would investigate cash flow improvement potential.